CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 13 enrolled
Drug / intervention
Clonidinedrug
Likely dose
Clonidine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01559012
NCT01559012Phase 3Completed
CompareCT.gov

The CLONEMESI Study: a Randomized Placebo-controlled Study With Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum.

A.O.U. Città della Salute e della Scienza·interventional·Posted Mar 20, 2012·Updated Apr 30, 2014

In Brief

A Phase 3 clinical trial evaluating Clonidine for Hyperemesis Gravidarum. Completed, enrolled 13 participants across 1 site.

Detailed Summary

CLONEMESI is an academic, independent, randomized placebo-controlled trial to assess the effect of transdermal (TD) clonidine in improving the symptoms of severe Hyperemesis Gravidarum(HG) affecting women in their 6th-12th week of pregnancy. The study has a crossover design.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperemesis Gravidarum
CountriesItaly
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 20, 2012
Enrollment StartFeb 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.3 years ago

Interventions

Clonidinedrug

transdermal clonidine patch 5 mg q. 5 days